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Abstract
Next-generation sequencing is being a robust technology for the practice of clinical diag-
nosis. The reason is that this technology offers the advantage of higher sensitivity and the 
potential to detect the full genome sequence of pathogens, including unknown patho-
gen species. In view of the exceptional advantages of next-generation sequencing, the 
technology can be used to improve and revolutionize conventional pathogenic detection 
methodologies. The technological result holds great possibilities in helping to support 
clinicians with richer insights into host’s genomic features, including the appropriateness 
to drug resistance based on the sequencing mapping of the microorganism. Besides, the 
technology will help discover the source of infection and insights into treatment direc-
tions, furthermore lead to the advancements in diagnosis. Eventually, this technology 
will benefit the clinical community in infectious disease prediction and prevention.
Keywords: pathogens, clinical disease, diagnosis, next-generation sequencing, disease 
biomarker
1. Introduction
Bacteria and virus consist of the most of the microbial pathogens. The microbial pathogens 
are responsible for infectious diseases causes in human hosts [1]. The microbial infections 
can cause the serious clinical symptoms in the human host, such as the inflammation, fever, 
pain and septic shock. They can even lead to the host death if the patient is treated with a 
delay. Thus, the early and accurate identification of pathogen is very important in clinical 
practice [2], as the proper antimicrobial treatment can be used to prevent the infection effec-
tively. However, the conventional diagnostics, like polymerase china reaction (PCR), enzyme-
linked immunosorbent assay (ELISA) and microbial cell culture, are lack of the ability for the 
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unknown or the high-mutated pathogens detection. Therefore, the novel pathogen diagnos-
tics is necessary for the clinical healthcare.
Next-generation sequencing (NGS) is the latest scientific technology till date to sequence the 
target gene or genome [3]. NGS technology refers to one high-throughput DNA sequenc-
ing method. In a single experiment, it can determine the sequence of the target gene or full 
genome with a total size of larger than millions of base pairs (bp) [4]. Sequencing thousands 
of genes or even genomes in one experiment is consequently made possible using this NGS 
technology.
Because of its robustness, NGS is widely being applied in biotechnologies, such as in foren-
sic biology, plant science and environmental contamination, etc., (Table 1). For example, the 
genome of Mycobacterium tuberculosis had been determined by Genome Analyzer to study the 
pathogen epidemiology [5]. In 2013, US Food and Drug Administration (FDA) has cleared 
Illumina MiseqDx to be the first in vitro NGS diagnosis platform [6]. In the recent years, with 
more development in this technology, NGS will provide more comprehensive information 
for the clinicians in clinical studies. In particular, there is more potential to translate currently 
available NGS technology into the pathogen detection.
2. The pathogen mutation is a challenge for infectious disease 
diagnosis
The microorganism pathogens are mostly responsible for the infection disease in the human 
body. PCR, ELISA and cell culture are the conventional methods for the pathogens detection 
[14]. However in PCR, one pair of primers, including forwards and reverse primers are com-
pulsory to design according to the target gene or genome spectrum. Meanwhile in ELISA, the 
functional antibodies are indispensable for the microorganism antigen detection. Finally for 
cell culture, the related culture medium is also required for the according microorganisms. 
Thus, these conventional methods will not be working for some unknown or high-mutated 









Table 1. The application of NGS in biotechnology.
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Furthermore, the pathogens, like virus and bacteria, have a high mutation rate which makes 
microorganism gene or proteins easily mutated [15]. The mutated gene would lead to the dra-
matic change of the protein structure [16]. The changed protein may be not be detected by the 
original antibody, as a result, it will be challenging for the identification of these pathogens 
using the conventional methods. Therefore, there is a limitation for the conventional methods 
to detect the unknown and high-mutated pathogenic species. These mutated species will lead 
to the drug resistance and other clinical problems. The problems will also compromise the 
success of current antimicrobial treatment, leading to further increase in pathogen infection 
incidence and host mortality. Hence, the more powerful sequencing technology is urgently 
needed in the clinic community.
3. The development of next-generation sequencing technology
The first method of sequencing DNA was developed by Sanger [17]. He first devised a 
method that allowed for the determination of small sequences in ribonucleic acids. The Sanger 
sequencing method was developed here using the chain termination technology. Because of 
his development, Sanger was awarded the Nobel Prize in 1980 [18]. At the beginning stage, 
the 3′ end of the primer anneals closely to the target DNA sequence. The addition of nucleo-
tides on the 3′ end of the template could either be a usual unlabeled nucleotide or a fluores-
cently labeled nucleotide. After that, no more nucleotides are able to bind to that particular 
strand of DNA sequence. This happens to all the templates that have been loaded into the 
Sanger sequencing platform and denatured into single strand DNA, leading to various single 
strands with different lengths and with diverse labeled nucleotides. As soon as the sequenc-
ing has ended, the finished sample would be denatured once again to remove the sequenced 
strands from the original loaded DNA. The sequenced strands would then be inputted into 
an Agarose gel for observing under a UV light. While the sample is undergoing Agarose gel 
running, it can be noted that the varying lengths of sequenced DNA would run at diverse 
times across the Agarose electrophoresis. The longer fragments are able to travel much slower 
than their shorter counterparts. The bands that will be then analyzed at the end of the gel. The 
result will be arranged according to their fragment size and labeling, therefore giving a visual 
image of the base sequence in the inputted sample. Sanger sequencing had been regarded as a 
gold standard metric because of its high accuracy. The method of the Sanger sequencing had 
been applied to sequence the first Homo sapiens genome [19].
However, even there are technological advances in the Sanger sequencing method such as the 
automation, the Sanger sequencing was still time-consuming and very costly. The growing 
interest in the sequencing of the personal genomes fueled the development of new robust 
technology. The NGS technology has been introduced currently. NGS has many functions, 
such as the sequencing of an entire genome, deep sequencing for a target region of the 
genome, or even multiplex sequencing which allows many samples to be sequenced at one 
time. In the NGS workflow (Figure 1), the multiplex sequencing function is utilized so that 
various samples can be sequenced simultaneously. The principle behind NGS platform is 
alike to that of Sanger sequencing. The signals produced from fluorescently or radioactively 
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labeled nucleotides are received, allowing the bases of the template DNA sequence to be read 
in order. But the difference between the two sequencing technologies is that NGS has the com-
petence to handle numerous sequencing reactions simultaneously. Many templates of DNA 
are able to be processed at the same time, which makes the whole genome sequencing time to 
be much more rapid with this robustness. Thus, NGS will be the next important sequencing 
tool used in biological and clinical samples as it offers a super speed with a higher accuracy.
Over these years, NGS technologies have matured and thus lowered cost and dramatically 
increased throughput. This technology eliminates the time-consuming and labor-intensive 
step to generate single clones via bacterial cloning and gel electrophoresis, and using the 
parallel processing to simultaneously sequence a large number of DNA sample. Thus, instead 
of generating hundreds of longer reads (more than 1000 bp), NGS technology produces mil-
lions of shorter reads (100 ~ 600 bp) ranging on the order of gigabases per run (Table 2). 
Consequently, the major work of sequencing has shifted from the benchtop to the desktop. 
For example, a nanopore NGS instrument MinION had been developed and applied for 
pathogens detection [20, 21]. Moreover the analysis of the NGS data presents new advance-
ments mainly due to the short read lengths and require significant investment in big data 
processing, including hardware, software and bioinformatics. Therefore, the high-throughput 
data is easily to be handled. As a result, what once took 1 week to sequence using Sanger 
sequencing can now be accomplished in a matter of days in a desktop NGS platform.
Superior to the traditional sequencing method, NGS is also able to sequence unknown DNA 
sequence. The unknown genome sequence can be de novo assembled. Depending on the  platforms 
Figure 1. The NGS workflow consists of library construction, sequencing and data analysis.
Sanger sequencing NGS
Experimental time ~1 week ~2 days
Cost per sample Expensive More cost-effective
Reads per sample One read Up to Millions
Reading length Long reading length Short reading length
Cloning vector required Yes No
Specific primer design Yes No
Gel electrophorese required Yes No
Table 2. Comparison of Sanger sequencing and NGS.
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used, NGS can sequence from tens of thousands to more than a billion molecules in a single 
sequencing running. And it is independent of the known microorganism sequence. In addition, 
NGS obtains this feature because of its ability to sequence thousands of the inputted sample, in a 
parallel style, rather than sequencing a single DNA template (Figure 1). This particularly parallel 
analysis is achieved by the miniaturization of the volume of the individual sequencing reaction, 
which limits the size of the instrument and reduces the cost of reagents per reaction.
4. Identification of the novel biomarkers through NGS
NGS technology proves to be a cost-effective, rapid, yet a highly sensitive method to sequence 
large amounts of DNA at once. This can enhance infectious disease research which may even-
tually lead to new biomarkers discoveries. These discoveries can be translated into new diag-
nostic, prognostic and therapeutic targets. In previous studies, NGS technology was used 
to detect the common mutation in viral samples from infected patients. Across the various 
samples analyzed, two common viral mutations were identified in all of the samples. A silent 
mutation and a missense mutation was detected. These common mutations identified code 
for viral reverse transcriptase subunits p66 and p51. As reverse transcriptase is extremely 
important for the survival of the virus, the common mutations identified are possible novel 
biomarkers for virus among local strains. With the identification of these novel biomarkers, it 
would serve to improve diagnosis as well as treatment.
In the particular study for pathogen diagnosis, NGS had allowed for the sequencing and 
identification of even the smallest variants of the viral or bacterial genome. The NGS results 
were able to illustrate the various base mutations that occurred across all multiple samples 
provided. Therefore, NGS has the robust advantage over conventional diagnostics of hav-
ing higher sensitivity, especially about low-frequent mutation or variants. This could be the 
reason that the traditional sequencing method counts on a given position when sequencing 
a determined DNA base. A minor mutation or variants will possibly have a low signal-to-
noise ratio that is unclear from the background noise. But for NGS, it makes use of complete 
coverage over the full gene or the whole genome which provides a much higher sensitivity 
regarding minor mutant or variant. From these results, perhaps these mutations would prove 
to have a rather significant impact on the drug-resistant capabilities of the virus. Further stud-
ies would be also extended to other viral or bacterial genome research. These will provide the 
characteristics of the microbial pathogens and the disease transmission pathways.
The common mutations identified at virus are located on the pol gene that codes for reverse 
transcriptase subunits [22]. Unlike other silent mutations, the missense mutation has more 
implications. As a result, there is an alteration in the corresponding amino acid from leucine 
to phenylalanine. Aligned with the reference genome, the protein function could be altered 
because of the missense mutation. The missense mutation would result in changes to the 
protein structure of reverse transcriptase, causing the conformational changes. These changes 
to the protein have potential to cause resistance to antimicrobial drugs, allowing the virus to 
continue developing in the host.
Explore the Novel Biomarkers through Next-Generation Sequencing
http://dx.doi.org/10.5772/intechopen.73205
7
Consequently drug resistance remains a challenge for the treatment of pathogen infection. 
It arises from the pathogen’s ability to mutate rapidly. The infected patients can initially be 
infected with a drug-resistant virus or develop drug resistance after starting therapy. Studies 
have been conducted to identify the mutations due to the resistance to antiviral medicines. 
More than 50 and 40 reverse transcriptase mutations have been found to be associated with 
nucleoside reverse transcriptase inhibitor (NRTI) and non-nucleoside reverse transcriptase 
inhibitor (NNRTI) drugs respectively [23]. The viral reverse transcriptase is highly impor-
tant as it catalyzes the conversion of single-stranded RNA to double-stranded viral DNA 
for integration into the host genome. This enzyme plays an important role in the life cycle 
of the virus and has been a good target for the development of antiretroviral drugs for the 
treatment of pathogens. Currently, there are two broad classes of drugs that target the viral 
reverse transcriptase; NRTI (like stavudine and emtricitabine) and NNRTI (like nevirapine 
and etravirine) [24].
The ability of the virus to mutate at the specific position may be due to the selective pressure. 
There is a high possibility that these mutations can be commonly observed in viral strains. 
The development of such mutations would allow for the survival and continuity of the local 
subtype virus. Hence, the identification of these common mutations could be used as novel 
biomarkers for the diagnosis. Studies have shown similar mutations identified in local viral 
strains. This further certifies that the mutation found is likely to be common in viral strains. 
Thus, the common mutations found through NGS technology can be applied as diagnostic 
biomarkers. Furthermore, it can be developed into the potential marker for the future drugs 
to defense against pathogens. This can significantly help the microbiological laboratories in 
large-scale studies of the virus, which aims to aid in the clinical management of pathogen 
infection [25]. Nevertheless, further studies should be done with a larger sample size to con-
firm if the identified common mutation is still observed in a larger population.
Compared with microbial culture, NGS technology is a culture-free detection methodology. 
Metagenomics sequencing will provide a fast, reliable tool for a rapid microbial diagnosis. The 
conservation region of 16 s ribosomal ribonucleic acid (rRNA) amplicons can be sequenced 
by a standard workflow. Thus, this methodology can identify hundreds or even thousands 
species at one time. The microbial system biology can be also investigated at the same time. 
The automated software or pipeline will help the metagenomics to be a standard microbial 
detection method.
The molecular epidemiology studies can be investigated deeply, using NGS results. And the 
investigation of subtype differences in clinical phenotypes and treatment outcomes can be 
achieved. It is fully predictable that NGS will be much better than the often used conven-
tional diagnosis methods, for providing sequence information for the genomic, microbiologi-
cal and clinical studies. The current standard of diagnosis methods, commercially available 
PCR, ELISA, cell culture or other assays target short sub-gene fragments for drug resistance 
determination. Furthermore, it is interesting to highlight that mutations outside these regions 
can influence drug resistance [26]. Additionally, NGS is more powerful to study of drug resis-
tance, and disease transmission [27]. There are many emerging multi-drug resistant organisms 
globally, thus it is significant to investigate the molecular microbiology of the new pathogens. 
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Antimicrobial therapy is widely performed as a form of treatment in fighting against pathogen 
infection. Unfortunately, some microorganism has the ability to rapidly mutate which results 
in changes in its genetic or protein structure. This provides pathogens with the potential to 
develop resistance to existing antimicrobial drug or treatment. NGS can provide the solution 
of sequencing a pathogenic gene/genome and the identification of a common mutation in the 
targeted region. The decrease in cost and increase in accuracy, resolution and reproducibility 
of NGS allows large-scale sequencing of the virus to be performed efficiently. The study made 
use of NGS platform together with the usage of the library preparation to sequencing the 
mutated pathogenic samples. The advancement of NGS has brought about many benefits to 
the field of biological sciences and will continue to play a big role in the disease diagnostics.
5. Future perspectives
By using NGS, the advantages of this technology was able to be observed throughout the dura-
tion of the experiments. One of the really good advantages includes the deep sequencing pro-
tocol that occurs during NGS. Deep sequencing is the process of sequencing the same region 
several times, from hundreds to ten of thousands times coverage. When amplicons are able to 
be sequenced at a really high depth of coverage, the sequence mutations can be highlighted. It 
allows for the detection of multiple variants that are really low in number within its popula-
tion. Somatic mutations that cannot be identified easily using the Sanger sequencing can be 
easily sequenced, making rare infectious diseases easier to study in a clinical environment.
However, the main NGS platforms used has a limited length of the sequence generated in 
individual reactions. The read length for the majority of platforms is in the range of hun-
dreds of base pairs. In order to sequence DNA longer than the feasible read length, the mate-
rial need fragmented before analysis. Following sequencing, the reads are analyzed through 
informatics to provide the information on the sequence of the whole target molecule. The 
short read, particularly the high-throughput sequencing methodology used in NGS was a dif-
ferent solution that developed sequencing competence. It enables population-scale sequenc-
ing and establishes a foundation for the novel genomic medicine as part of healthcare. NGS 
technologies are increasingly used for diagnosis and monitoring of infectious diseases such as 
virus infection. NGS is more powerful than other methods, such as Sanger sequencing, espe-
cially in the improved accuracy of the unkown region. The new technology is less costly and 
is more capable to detect the repeated fragments. Although the usage of NGS still has its set-
backs, such as the relatively expensive price of the sequencing consumables required to con-
duct one sequencing run, perhaps in the near future the overall cost of NGS will be reduced; 
with increased popularity of this sensational sequencing method, NGS will eventually be as a 
cheap and standard method in biomarker discovery. Also, an adapted genotyping prediction 
informatics could be developed based on data acquired from whole-genome sequences of 
drug-resistant isolates. The predicted novel treatment resistance conferring mutations would 
be validated against phenotypic assay as well as clinical data acquired from the patients. The 
correlative application between the new solution and the conventional methods, such as PCR 
would be also determined together to assess the performance of the drugs.





ELISA Enzyme-linked immunosorbent assay
NGS Next-generation sequencing
NNRTI Non-nucleoside reverse transcriptase inhibitor
NRTI Nucleoside reverse transcriptase inhibitor
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